Which FDA‑approved oral liquid medications are available for a 12‑year‑old child?

FDA-Approved Oral Liquid Medications for 12-Year-Olds

For a 12-year-old child, multiple FDA-approved oral liquid medications are available across various therapeutic categories, with linezolid oral suspension (20 mg/kg/day in 2 doses) being specifically approved for children ≥12 years for resistant infections, and oseltamivir oral suspension (6 mg/mL concentration) approved down to 2 weeks of age for influenza treatment.

Key FDA-Approved Liquid Formulations by Category

Antibiotics for Community-Acquired Pneumonia

For children ≥12 years old, the following oral liquid options are FDA-approved 1:

• Linezolid oral suspension: 20 mg/kg/day in 2 divided doses (specifically for ≥12 years)

  • Used for resistant S. pneumoniae (MIC ≥4.0 μg/mL) and MRSA infections
  • Alternative to parenteral therapy when oral step-down is appropriate

• Amoxicillin liquid: 90 mg/kg/day in 2 doses or 45 mg/kg/day in 3 doses

  • First-line for S. pneumoniae with penicillin MIC >2.0 μg/mL
  • Available in multiple suspension concentrations

• Amoxicillin-clavulanate suspension: 45 mg/kg/day in 3 doses or 90 mg/kg/day in 2 doses (amoxicillin component)

  • For β-lactamase producing H. influenzae

• Clindamycin oral solution: 30-40 mg/kg/day in 3-4 doses

  • For MRSA susceptible to clindamycin
  • Alternative for Group A Streptococcus

Macrolides (Liquid Formulations)

• Azithromycin oral suspension: 10 mg/kg on day 1, then 5 mg/kg/day once daily on days 2-5 1

  • Preferred for M. pneumoniae and C. pneumoniae
  • FDA-approved for pediatric use

• Clarithromycin suspension: 15 mg/kg/day in 2 doses

  • Alternative macrolide option

• Erythromycin oral suspension: 40 mg/kg/day in 4 doses

  • Available but less preferred due to tolerability

Antivirals

Oseltamivir oral suspension is FDA-approved for children as young as 2 weeks 2:

• Concentration: 6 mg/mL in 60-mL bottles (commercially manufactured)
• Dosing: Weight-based dosing per FDA label
• Alternative preparation: If commercial suspension unavailable, capsules can be opened and mixed with simple syrup or Ora-Sweet SF to 6 mg/mL concentration by retail pharmacies
• Treatment window: Most effective when started within 48 hours of symptom onset, though benefit exists even after 48 hours in moderate-to-severe disease

Cephalosporins (Oral Liquids)

Multiple second- and third-generation cephalosporins available as suspensions 1:

• Cefpodoxime, cefuroxime, cefprozil suspensions
• Cefdinir, cefixime, ceftibuten suspensions
• Used as alternatives for resistant pneumococcal infections or H. influenzae

Critical Formulation Considerations

Dosing Device Consistency

Important safety note: At the time of FDA guidance implementation, 98.6% of pediatric OTC liquid medications had inconsistencies between dosing directions and measuring device markings 3. When prescribing:

• Verify that measuring device markings match prescribed dose
• Avoid atypical units (drams, cc)
• Use standardized abbreviations (mL, not ml or cc)
• Ensure device is included with prescription

Sweetener Content

Liquid formulations contain varying sweeteners 4:

• 62% of pediatric-friendly formulations incorporate flavorings and aromas 5
• Sucrose content varies widely (0-80% depending on product)
• Consider sugar-free alternatives for patients with diabetes or dental concerns

Common Pitfalls to Avoid

1. Assuming all drugs have liquid formulations: Only 44% (188/425) of drugs with pediatric labeling have pediatric-friendly formulations available 5

2. Overlooking formulation manipulation requirements: 38% of pediatric-friendly formulations require manipulation (powder/granule, sprinkle/pellet, dispersible tablet) rather than direct administration 5

3. Delaying antiviral treatment: For influenza, oseltamivir should be started immediately without waiting for confirmatory testing, as early therapy provides best outcomes 2

4. Using adult solid dosage forms: For 53.8% of pediatric labeling changes, only solid oral dosage forms were commercially available, often at sizes exceeding reasonable thresholds for the age group 5

Age-Specific Dosing Transitions

At 12 years old, several medications transition from pediatric to adolescent dosing 1:

• Linezolid: Changes from 30 mg/kg/day in 3 doses (<12 years) to 20 mg/kg/day in 2 doses (≥12 years)
• Levofloxacin: Transitions from 16-20 mg/kg/day in 2 doses to 8-10 mg/kg/day once daily (5-16 years)
• Maximum daily doses should not exceed adult doses regardless of weight-based calculations